| Předmět: |
|
| Zdroj: |
Drug Week; 12/6/2024, p2311-2311, 1p |
| Abstrakt: |
Researchers at Osaka University conducted a study comparing two compounds targeting fibroblast activation protein a (FAPa) for nuclear medicine therapeutics. The study found that doubling the linker length in the compounds increased tumor retention and altered the excretion pathway, potentially reducing toxicity. While no significant differences were observed in the anti-tumor effects of the compounds, it was confirmed that the linker length affects the biological half-life. This research provides valuable insights into the development of novel nuclear medicine therapeutics for cancer treatment. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
